Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Montanide ISA 51 + Sargramostim + WT1 vaccine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Montanide ISA 51 | ||||
Sargramostim | Leukine | GM-CSF|Prokine | ||
WT1 vaccine | Multiple vaccines consisting of a variety of synthetic peptides derived from the human Wilms' Tumor (WT1) Protein used to induce a cytotoxic T-cell lymphocyte response against cells expressing WT1 (PMID: 25699052). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01265433 | Phase II | Montanide ISA 51 + Sargramostim Montanide ISA 51 + Sargramostim + WT1 vaccine | WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Completed | USA | 0 |